We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
-4.38%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$129M
AUM Growth
–
Cap. Flow
+$136M
Cap. Flow %
105.61%
Top 10 Hldgs %
77.29%
Holding
27
New
27
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
JSPR icon
Jasper Therapeutics
JSPR
+$30.1M
2
LNTH icon
Lantheus
LNTH
+$16.5M
3
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$13.3M
4
IMCR icon
Immunocore
IMCR
+$10.6M
5
ADMA icon
ADMA Biologics
ADMA
+$7.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 88.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JSPR icon
1
Jasper Therapeutics
JSPR
$23.6M
$22.9M 17.81%
+321,904
New +$30.1M
LNTH icon
2
Lantheus
LNTH
$6.59B
$18M 13.94%
+621,753
New +$16.5M
SNCE
3
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$15M 11.61%
+60,000
New +$13.3M
IMCR icon
4
Immunocore
IMCR
$1.73B
$10M 7.8%
+293,385
New +$10.6M
ITCI
5
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.85M 6.09%
+150,000
New +$6.3M
ADMA icon
6
ADMA Biologics
ADMA
$2.22B
$7.61M 5.91%
+5,397,798
New +$7.1M
STLN
7
Starling Oncology, Inc. Common Stock
STLN
$641M
$5.85M 4.54%
+600,000
New +$5.33M
NMTR
8
DELISTED
9 Meters Biopharma
NMTR
$4.24M 3.29%
+216,415
New +$4.84M
NYXH
9
Nyxoah
NYXH
$147M
$4.09M 3.17%
+177,679
New +$4.09M
RAPT
10
DELISTED
RAPT Therapeutics
RAPT
$4.04M 3.14%
+13,750
New +$3.68M
TELA icon
11
TELA Bio
TELA
$38.9M
$3.84M 2.98%
+300,000
New +$3.8M
CRBU icon
12
Caribou Biosciences
CRBU
$164M
$3.18M 2.47%
+210,695
New +$4.1M
CFMS
13
DELISTED
Conformis, Inc. Common Stock
CFMS
$3.17M 2.46%
+166,664
New +$4.27M
SLGC
14
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$2.74M 2.13%
+235,300
New +$2.82M
CMRX
15
DELISTED
Chimerix, Inc.
CMRX
$2.57M 2%
+400,000
New +$2.4M
SNDA icon
16
Sonida Senior Living
SNDA
$1.91B
$2.36M 1.83%
+82,832
New +$2.51M
HCSG icon
17
Healthcare Services Group
HCSG
$1.53B
$2.19M 1.7%
+123,000
New +$2.39M
LITS
18
Lite Strategy Inc
LITS
$30.9M
$2M 1.55%
+37,388
New +$2.09M
RDUS
19
DELISTED
Radius Health, Inc.
RDUS
$1.91M 1.48%
+275,281
New +$4.04M
RZLT icon
20
Rezolute
RZLT
$452M
$1.43M 1.11%
+300,000
New +$1.75M
XERS icon
21
CALL
Xeris Biopharma Holdings
XERS
$1.45B
$1.31M 1.02%
+446,500
New +$964K
CRIS icon
22
Curis
CRIS
$7.83M
$1.19M 0.92%
+625
New +$1.49M
NKGN
23
DELISTED
NKGen Biotech, Inc. Common Stock
NKGN
$836K 0.65%
+86,506
New +$842K
NVNO
24
enVVeno Medical
NVNO
$7.09M
$491K 0.38%
+2,128
New +$599K
NKGNW
25
DELISTED
NKGen Biotech, Inc. Warrants
NKGNW
$23K 0.02%
+20,000
New +$20.3K
1
2

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
RFS
Richardson Financial Services Medway, Massachusetts $160M AUM 16.71% 1-Year Est. Return
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
CF
CBM Financial Austin, Texas $160M AUM

Velan Capital Investment Management's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for Velan Capital Investment Management, which disclosed 27 positions worth $129M. Its ten largest holdings account for 77% of the portfolio.

Its largest position is Jasper Therapeutics: 321,904 shares worth $22.9M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets.

  • Velan Capital Investment Management's largest Q4 2021 buy was Jasper Therapeutics: 321,904 shares worth $22.9M.
  • Velan Capital Investment Management's ten largest holdings make up 77% of its $129M portfolio in Q4 2021.
  • Velan Capital Investment Management disclosed 27 positions in Q4 2021, its first 13F filing on record.

Based on Velan Capital Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.